Tight glucose control may preserve insulin-making cells in type 2 diabetes

NCT ID NCT05040087

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This trial tests whether adjusting diabetes medications to keep blood sugar levels in the normal range can preserve the body's insulin-producing beta-cells and slow the natural worsening of type 2 diabetes. Adults aged 40 to 75 with type 2 diabetes will be assigned to either usual care guided by HbA1c or intensive care guided by self-monitored blood glucose. Researchers will compare changes in beta-cell function, blood sugar control, and diabetes-related eye and kidney complications between the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
intensification of diabetes medication based on self-monitored blood glucose levels
What this could lead to
If successful, this approach could help preserve the body's own insulin production and slow the worsening of type 2 diabetes, potentially reducing complications and healthcare costs.
What could go wrong
This is a relatively small study, and the intensive glucose monitoring required may be burdensome. It is not yet known whether this strategy will meaningfully preserve beta-cell function or prevent complications over the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Atlanta VA Medical Center

    Decatur, Georgia, 30033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.